Contact
searchSearch
HMP Global
Login

Major Depressive Disorder Topic Center

Conference attendees look at a poster
Conference Coverage
Digital Therapeutic Rejoyn May Aid Anxiety in MDD Patients
09/25/2025
Brionna Mendoza
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn (CT-152) outperformed a sham smartphone app in reduction of anxiety levels in adult patients with major depressive disorder (MDD).
The digital therapeutic Rejoyn...
09/25/2025
Psych Congress Network
A poster hall at a conference
Conference Coverage
Added Seltorexant Shows Robust Response With Fewer Adverse Events in MDD With Insomnia
09/19/2025
Jolynn Tumolo
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major...
09/19/2025
Psych Congress Network
DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network
quiz
Quiz
Oral Fluoxetine Dosing for Adults With Major Depressive Disorder
06/12/2025
Meagan Thistle
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology...
06/12/2025
Psych Congress Network
brain graphic
News
Fremanezumab Reduces Migraine Days, Depressive Symptoms in Patients with Migraine and Comorbid MDD
06/02/2025
Jolynn Tumolo
Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo,...
06/02/2025
Psych Congress Network
woman experiencing depression
News
LMF Effective as Adjunct Treatment in SSRI-Resistant Depression, Review Finds
05/12/2025
Maria Mantas
According to a recent literature review, L-methylfolate (LMF) is an effective adjunct treatment in selective serotonin reuptake inhibitor (SSRI)-resistant depression, particularly at 15 mg/day.
According to a recent literature review, L-methylfolate (LMF) is an effective adjunct treatment in selective serotonin reuptake inhibitor (SSRI)-resistant depression, particularly at 15 mg/day.
According to a recent literature...
05/12/2025
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network
A woman taking a pill
News
New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms
04/09/2025
Maria Mantas
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more...
04/09/2025
Psych Congress Network

News

DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network
brain graphic
News
Fremanezumab Reduces Migraine Days, Depressive Symptoms in Patients with Migraine and Comorbid MDD
06/02/2025
Jolynn Tumolo
Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo, fremanezumab significantly reduced both monthly migraine days and depressive symptoms in patients with migraine and moderate to severe comorbid MDD, according to a study published in JAMA Neurology.
Compared with placebo,...
06/02/2025
Psych Congress Network
woman experiencing depression
News
LMF Effective as Adjunct Treatment in SSRI-Resistant Depression, Review Finds
05/12/2025
Maria Mantas
According to a recent literature review, L-methylfolate (LMF) is an effective adjunct treatment in selective serotonin reuptake inhibitor (SSRI)-resistant depression, particularly at 15 mg/day.
According to a recent literature review, L-methylfolate (LMF) is an effective adjunct treatment in selective serotonin reuptake inhibitor (SSRI)-resistant depression, particularly at 15 mg/day.
According to a recent literature...
05/12/2025
Psychiatry & Behavioral Health
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network
A woman taking a pill
News
New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms
04/09/2025
Maria Mantas
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more...
04/09/2025
Psych Congress Network
Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
Pill bottle
News
Investigational MDD Drug Shows Favorable Outcome in Interim Analysis
02/18/2025
Jolynn Tumolo
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial investigating adjunctive ALTO-300 in patients with MDD and inadequate antidepressant response will add 50 participants after results from a planned interim analysis showed favorable findings, Alto Neuroscience...
An ongoing phase 2b trial...
02/18/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Jolynn Tumolo
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
Katherine Warburton, Stephen Stahl, and Roberto Carrara
News
Breaking the Cycle of Criminalization: Keynote Address Tackles Neuroethics, Justice Reform, and Patient Autonomy at Psych Congress 2025
09/19/2025
Maria Mantas
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.
Discussions of ethical...
09/19/2025
Psych Congress Network
DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
cannabis plant and CBD oil
News
High Levels of THC in Cannabis Products Associated With Mental Health Risks
09/11/2025
Maria Mantas
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained...
09/11/2025
Psych Congress Network
child embraces mother
News
Child Depression During COVID-19 Pandemic Associated With Subsequent Maternal Depression
09/02/2025
Maria Mantas
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and...
09/02/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Early ADHD Drug Treatment Linked With Reduced Risk of Suicide, Substance Misuse, and Other Adverse Outcomes
08/27/2025
Jolynn Tumolo
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with...
08/27/2025
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Investigational App for Negative Schizophrenia Symptoms Meets Primary Trial Endpoint
08/25/2025
Jolynn Tumolo
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription...
08/25/2025
Psych Congress Network
tired man rubs eyes
News
Vulnerability to Inflammation-Related Depression Exaggerated in Older Adults With Insomnia
08/18/2025
Jolynn Tumolo
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults...
08/18/2025
Psych Congress Network
A woman lies in bed awake due to insomnia
News
Cannabinoids Produce Worse Sleep Outcomes in Small Pilot Study
08/15/2025
Brionna Mendoza
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of...
08/15/2025
Neurology

Quizzes

quiz
Quiz
Oral Fluoxetine Dosing for Adults With Major Depressive Disorder
06/12/2025
Meagan Thistle
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology knowledge: What is the recommended starting dose of oral fluoxetine for MDD in adults? The maximum dose should not exceed how many mg per day?
Test your psychopharmacology...
06/12/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
Meagan Thistle
12/11/2024
Psych Congress Network
quiz
Quiz
What is esketamine indicated to treat?
12/02/2024
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of what? Take the quiz!
Esketamine, a non-competitive...
12/02/2024
Psych Congress Network
quiz
Quiz
Key Barriers to Tardive Dyskinesia Diagnosis
11/18/2024
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive dyskinesia diagnosis DID NOT include which of the following, according to data presented in a poster at Psych Congress 2024? Take the quiz now!
The key barriers to a tardive...
11/18/2024
Psych Congress Network
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
brain puzzle graphic
Quiz
Treatment Guidelines for Patients With MDD Who Have Not Responded to Current Pharmacotherapy
09/09/2024
Patients with MDD who have undergone an adequate trial of optimized pharmacotherapy but only partial or no response should be reassessed for what? Take the quiz to find out!
Patients with MDD who have undergone an adequate trial of optimized pharmacotherapy but only partial or no response should be reassessed for what? Take the quiz to find out!
Patients with MDD who have...
09/09/2024
Psych Congress Network
a cloud with three z's
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 1)
09/19/2025
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control and protect sleep? Take this quick quiz on viloxazine ER’s role in patients with nighttime challenges.
Can you optimize ADHD control...
09/19/2025
Psych Congress Network
Dr Greg Mattingly
Quiz
Test Your Knowledge – Viloxazine ER: A New Era in ADHD Treatment?
09/17/2025
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the clinical impact and unique mechanism of viloxazine ER? Take this short quiz to find out.
How well do you know the...
09/17/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Craig Chepke, MD, DFAPA
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
medication
Quiz
Test Your Knowledge: Study Results Link Non-Stimulant ADHD Therapy and Prescription Stimulant Misuse in Adolescents
09/09/2025
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about...
09/09/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge – Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
09/04/2025
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of...
09/04/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge: Dr Rakesh Jain on Nonstimulant Treatment Options for Pediatric ADHD
09/03/2025
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the...
09/03/2025
Psych Congress Network
Wooden blocks spelling QUIZ
Quiz
Test Your Knowledge: Viloxazine ER Added to Stimulant Treatment for Pediatric ADHD Appears Safe, Effective
09/02/2025
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance...
09/02/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Quiz
Test Your Knowledge – Navigating ADHD Care Forward: The Future of ADHD
08/27/2025
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test...
08/27/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Quiz
Test Your Knowledge – Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
08/25/2025
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER...
08/25/2025
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Initiating Clozapine in Patients With Schizophrenia
08/15/2025
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following...
08/15/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use